Imagine your immune system is a security team that sometimes misses a few intruders. This technology uses AI to find the exact 'fingerprint' of a patient's tumor and then trains the patient's own immune cells in a lab to recognize that specific mark. Once these super-charged cells are put back into the body, they act like guided missiles that only hit cancer cells, leaving healthy tissue alone.
Current cancer immunotherapies often fail in solid tumors because immune cells cannot effectively infiltrate the tumor. There is a high unmet medical need for treatments that can precisely target individual patient mutations without harming healthy cells.
A personalized T-cell therapy system consisting of PIOR® AI software for neoantigen identification and EpiTCer® for T-cell activation.
If you are a cell therapy developer dealing with low immune cell infiltration in solid tumors — this project developed pTTL that uses AI to target neoantigens and increase tumor-reactive T-cell clones. This allows for a more precise attack on cancers with high unmet medical needs.
If you are a clinic dealing with advanced Stage IV colorectal cancer patients — this project developed a personalized T-cell therapy that is designed to be cost-effective and easy to implement. It provides a scalable way to offer individualized treatment based on a patient's own lymph nodes.
If you are a diagnostics firm dealing with the difficulty of identifying tumor-specific mutations — this project developed PIOR® machine learning software that selects and designs targetable neoantigens. This software streamlines the identification process for personalized medicine.
Based on available project data, the specific price per treatment is not listed, but the project objective is to ensure the therapy is cost-effective and easy to implement.
The project aims to optimize the pTTL manufacturing process for future clinical trials and has already performed preparations for manufacturing scale-out.
The therapy is based on two proprietary technologies: PIOR® machine learning software and EpiTCer®.
A phase I/IIa First in Human clinical trial is currently ongoing, with the project running from 2023-11-01 to 2026-07-31.
It is an autologous therapy where T-cells are harvested from regional lymph nodes, trained in a lab, and then re-infused into the patient.
The project is led by a single Swedish SME, NEOGAP THERAPEUTICS AB, which holds 100% of the industry ratio. This lean structure suggests a highly focused development path where the company controls both the AI software (PIOR®) and the delivery technology (EpiTCer®), reducing coordination overhead but placing all execution risk on one entity.
Contact NEOGAP THERAPEUTICS AB in Sweden
Contact us to explore licensing opportunities for PIOR® and EpiTCer® technologies.
